Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 6/20 | 0.43 |
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.43 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.43 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.43 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.43 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL3329978 | 0.85 | SLC6A4 (0.43) | ADRA2CSLC6A4SLC6A2HTR2ASLC6A3 | |
| Fumaric Acid SCHEMBL3330858 | 0.77 | SLC6A4 (0.43) | ADRA2CSLC6A4SLC6A2HTR2ASLC6A3 | |
| Fumaric Acid SCHEMBL3330285 | 0.77 | ADRA2C (0.46) | ADRA2CSLC6A4SLC6A2HTR2ASLC6A3 | |
| Viloxazine SCHEMBL27193019 | 0.74 | SLC6A2 (0.80) | ADRA2CSLC6A4SLC6A2HTR2ASLC6A3 | |
| Viloxazine SCHEMBL3187008 | 0.74 | SLC6A2 (0.80) | ADRA2CSLC6A4SLC6A2HTR2ASLC6A3 | |
| (S)-Viloxazine SCHEMBL3186997 | 0.74 | SLC6A2 (0.80) | ADRA2CSLC6A4SLC6A2HTR2ASLC6A3 | |
| (S)-Viloxazine SCHEMBL3187012 | 0.74 | SLC6A2 (0.80) | ADRA2CSLC6A4SLC6A2HTR2ASLC6A3 | |
| Fumaric Acid SCHEMBL10846125 | 0.71 | ADRA2C (0.57) | ADRA2CSLC6A4SLC6A2HTR2ASLC6A3 | |
| Maleic Acid SCHEMBL10846767 | 0.71 | ADRA2C (0.57) | ADRA2CSLC6A4SLC6A2HTR2ASLC6A3 | |
| Fumaric Acid SCHEMBL10846113 | 0.71 | ADRA2C (0.57) | ADRA2CSLC6A4SLC6A2HTR2ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| EP-1744754-A1 | MORPHOLINE COMPOUNDS | Pfizer Limited (GB) | 2007-01-24 | — | — | EP | disclosed |
| US-20050250775-A1 | Novel compounds | FISH PAUL V | 2005-11-10 | — | — | US | disclosed |
| WO-2005105100-A1 | MORPHOLINE COMPOUNDS | PFIZER LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250775-A1 | Novel compounds | OPRL1, UGT1A1, NPSR1 | SLC6A4 114/4885SLC6A2 133/4885HTR2A 108/4885 |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | OPRL1, MYLK2, TNNT2 | SLC6A4 350/4885SLC6A2 201/4885HTR2A 30/4885 |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | SLC6A4 113/4885SLC6A2 109/4885HTR2A 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.